Contrasting Cytosorbents (NASDAQ:CTSO) & Caliber Imaging & Diagnostics (OTCMKTS:LCDX)

Cytosorbents (NASDAQ:CTSO) and Caliber Imaging & Diagnostics (OTCMKTS:LCDX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Profitability

This table compares Cytosorbents and Caliber Imaging & Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-68.70%	-131.84%	-50.72%
Caliber Imaging & Diagnostics	N/A	N/A	N/A

Valuation & Earnings

This table compares Cytosorbents and Caliber Imaging & Diagnostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$32.93 million	1.67	-$28.51 million	($0.59)	-1.71
Caliber Imaging & Diagnostics	N/A	N/A	N/A	($0.75)	N/A

Caliber Imaging & Diagnostics has lower revenue, but higher earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Caliber Imaging & Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Cytosorbents and Caliber Imaging & Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	0	1	1	1	3.00
Caliber Imaging & Diagnostics	0	0	0	0	N/A

Cytosorbents currently has a consensus price target of $2.00, indicating a potential upside of 98.02%.

Insider and Institutional Ownership

32.9% of Cytosorbents shares are held by institutional investors. 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Cytosorbents beats Caliber Imaging & Diagnostics on 6 of the 10 factors compared between the two stocks.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics, Inc., a medical technologies company, designs, develops, and markets imaging solutions that shows tissue at the cellular level in the United States. The company provides VivaScope 1500, a reflectance confocal imaging system that enables clinicians and researchers to capture confocal images that depict cellular structures of living tissue; and VivaScope 3000, a hand-held in vivo reflectance confocal microscope for skin imaging. It also offers VivaScan software to schedule patients for examinations, perform imaging examinations on one or more lesions during a visit, review, and report on images obtained during an examination, as well as VivaNet, a digital telepathology system. The company was formerly known as Lucid, Inc. and changed its name to Caliber Imaging & Diagnostics, Inc. in August 2012. Caliber Imaging & Diagnostics, Inc. was founded in 1991 and is headquartered in Andover, Massachusetts.